BIAF
bioAffinity Technologies, Inc.
NASDAQ: BIAF · HEALTHCARE · DIAGNOSTICS & RESEARCH
$2.49
+2.26% today
Updated 2026-04-30
Market cap
$10.03M
P/E ratio
—
P/S ratio
1.63x
EPS (TTM)
$-8.66
Dividend yield
—
52W range
$1 – $15
Volume
10.8M
bioAffinity Technologies, Inc. (BIAF) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $1306.00 | $4803.00 | $2.53M | $9.36M | $6.16M |
| Revenue growth (YoY) | — | — | — | +267.8% | +52617.1% | +269.7% | -34.2% |
| Cost of revenue | $40278.00 | $22242.00 | $4817.00 | $467.00 | $1.74M | $5.98M | $4.73M |
| Gross profit | $-40278.00 | $-22242.00 | $-4817.00 | $4336.00 | $791615.00 | $3.38M | $1.43M |
| Gross margin | — | — | -368.8% | 90.3% | 31.3% | 36.1% | 23.2% |
| R&D | $1.85M | $1.61M | $1.33M | $1.52M | $1.73M | $1.78M | $2.09M |
| SG&A | — | $994343.00 | $880772.00 | $2.73M | $6.79M | $9.94M | $9.91M |
| Operating income | $-3.09M | $-2.60M | $-2.21M | $-4.01M | $-7.97M | $-8.95M | $-10.57M |
| Operating margin | — | — | -168975.7% | -83511.5% | -314.9% | -95.6% | -171.6% |
| EBITDA | $-3.05M | $-6.86M | $-5.32M | $-5.61M | $-7.63M | $-8.33M | $-10.07M |
| EBITDA margin | — | — | -407181.6% | -116777.7% | -301.3% | -89.0% | -163.4% |
| EBIT | $-3.09M | $-6.88M | $-5.32M | $-5.62M | $-7.88M | $-8.94M | $-10.57M |
| Interest expense | $214834.00 | $382171.00 | $1.00M | $2.53M | $37125.00 | $92475.00 | $44372.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-3.31M | $-7.27M | $-6.33M | $-8.15M | $-7.94M | $-9.04M | $-14.91M |
| Net income growth (YoY) | — | -119.8% | +13.0% | -28.9% | +2.7% | -13.9% | -64.9% |
| Profit margin | — | — | -484411.4% | -169771.2% | -313.5% | -96.6% | -242.0% |